Cargando…
The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
PURPOSE OF REVIEW: Studies show that inhibitors of Bruton’s tyrosine kinase (BTKis), currently FDA-approved for the treatment of B cell malignancies, can prevent IgE-mediated reactions through broad inhibition of the FcεRI signaling pathway in human mast cells and basophils. This review will summari...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050815/ https://www.ncbi.nlm.nih.gov/pubmed/33880321 http://dx.doi.org/10.1007/s40521-021-00286-y |